FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Todd Lorenz

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Renato D Lopes; Todd J Lorenz; Michael J Mack; Rajendra H Mehta; Eric D Peterson; Eric M Reyes; Judson B Williams; Keith B Allen; Robert M Califf; T. Bruce Ferguson; C Michael Gibson; Gail E Hafley; Robert A Harrington; Nicholas T Kouchoukos; John H Alexander
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barrie Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
John H Alexander; Gail E Hafley; Robert A Harrington; eric peterson; T. Bruce Ferguson; Todd J Lorenz; Abhinav Goyal; Michael Gibson; Michael J Mack; Daniel Gennevois; Robert M Califf; Nicholas T Kouchoukos
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Todd Lorenz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Renato D Lopes; Todd J Lorenz; Michael J Mack; Rajendra H Mehta; Eric D Peterson; Eric M Reyes; Judson B Williams; Keith B Allen; Robert M Califf; T. Bruce Ferguson; C Michael Gibson; Gail E Hafley; Robert A Harrington; Nicholas T Kouchoukos; John H Alexander
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
American heart journal 2012;164(3):379-386.e1.
2009: Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barrie Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
American heart journal 2009;157(2):271-7.
2005: John H Alexander; Gail E Hafley; Robert A Harrington; eric peterson; T. Bruce Ferguson; Todd J Lorenz; Abhinav Goyal; Michael Gibson; Michael J Mack; Daniel Gennevois; Robert M Califf; Nicholas T Kouchoukos
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2005;294(19):2446-54.
2005: Abdul R Halabi; John H Alexander; Linda K Shaw; Todd J Lorenz; Lawrence Liao; David F Kong; Carmelo A Milano; Robert A Harrington; Peter K Smith
Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery.
The American journal of cardiology 2005;96(9):1254-9.
2005: John H Alexander; T. Bruce Ferguson; Diane M Joseph; Michael J Mack; Randall K Wolf; C Michael Gibson; Daniel Gennevois; Todd J Lorenz; Robert A Harrington; eric peterson; Kerry L Lee; Robert M Califf; Nicholas T Kouchoukos
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.
American heart journal 2005;150(4):643-9.
2003: James E Tcheng; Mina Madan; J Conor O'Shea; Eric A Cohen; Christopher E Buller; A Michael Lincoff; Jeffrey J Popma; Paul S Teirstein; Michael M Kitt; Todd J Lorenz; Sally Greenberg; NORMAN FOST; Robert M Califf
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
Journal of interventional cardiology 2003;16(2):97-105.
2002: Laura S Fernandes; James E Tcheng; J Conor O'Shea; Bonnie Weiner; Todd J Lorenz; Cindy Pacchiana; Lisa G Berdan; Kelly Maresh; Diane Joseph; Mina Madan; Tift Mann; Rakhi Kilaru; Judith S Hochman; Neal S Kleiman
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
Journal of the American College of Cardiology 2002;40(6):1085-91.
2002: C Michael Gibson; Sabina A Murphy; Susan J Marble; David J Cohen; Eric A Cohen; Henry K Lui; Jeffrey Young; Michael M Kitt; Todd J Lorenz; James E Tcheng
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.
American heart journal 2002;143(1):106-10.
2001: James E Tcheng; J D Talley; J Conor O'Shea; Ian C Gilchrist; Neal S Kleiman; Cindy L Grines; C J Davidson; A Michael Lincoff; Robert M Califf; L K Jennings; Michael M Kitt; Todd J Lorenz
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
The American journal of cardiology 2001;88(10):1097-102.
2001: James E Tcheng; John Strony; Todd J Lorenz; J Conor O'Shea
ESPRIT in context: pharmacology matters!
European heart journal 2001;22(21):1965-7.
2001: I C Gilchrist; J Conor O'Shea; T Kosoglou; L K Jennings; Todd J Lorenz; Michael M Kitt; Neal S Kleiman; D Talley; FV Aguirre; C Davidson; J Runyon; James E Tcheng
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Circulation 2001;104(4):406-11.
2001: C Michael Gibson; David J Cohen; Eric A Cohen; Henry K Lui; Sabina A Murphy; Susan J Marble; Michael M Kitt; Todd J Lorenz; James E Tcheng
Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.
The American journal of cardiology 2001;87(11):1293-5.
2001: J Conor O'Shea; Gail E Hafley; Sally Greenberg; Vic Hasselblad; Todd J Lorenz; Michael M Kitt; John Strony; James E Tcheng
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2001;285(19):2468-73.
2000: J Conor O'Shea; Mina Madan; Warren J Cantor; Cindy M Pacchiana; Sally Greenberg; Diane M Joseph; Michael M Kitt; Todd J Lorenz; James E Tcheng
Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
American heart journal 2000;140(6):834-9.
2000: Neal S Kleiman; A Michael Lincoff; G C Flaker; Karen S Pieper; Robert G Wilcox; Lisa G Berdan; Todd J Lorenz; D V Cokkinos; Maarten L Simoons; E Boersma; Eric J Topol; Robert M Califf; Robert A Harrington
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
Circulation 2000;101(7):751-7.
1999: Todd J Lorenz; F Macdonald; Michael M Kitt
Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa.
Clinical therapeutics 1999;21(1):128-37.